



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Thursday June 05, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
TLXAO	SHARE APPRECIATION RIGHTS	1,541,188	30/05/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

5/6/2025



## Part 2 - Issue details

---

### **2.1 The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

### **2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

**Date the +securities the subject of this notification were issued**

30/5/2025

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	98,003
David Cade	David Cade	74,684

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

Refer to Telix's Remuneration report, within its 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Performance Share Appreciation Rights (PSARs) (exercise price: \$28.67) granted to Telix employees ex-US as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and a two year exercise period following vesting. For further details refer to the Remuneration report in Telix's 2024 Annual Report accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

## Issue details

**Number of +securities**

1,534,027

**ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

**Date the +securities the subject of this notification were issued**

30/5/2025



**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

No

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

Refer to Telix's Remuneration report, within its 2022-2024 Annual Reports accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Performance Share Appreciation Rights (PSARs) (exercise price: \$4.95) granted to select Telix ex-US employees upon vesting of 2022 Long Term Incentive to reflect an inadvertent administrative error, and with a two year exercise period from vesting. For further details refer to the Remuneration report in Telix's 2022-2024 Annual Reports accessible at <https://telixpharma.com/investor-centre/financial-reports-presentations/>

---

#### Issue details

**Number of +securities**

7,161

---

Part 4 - +Securities on issue

---

**Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	338,109,048

**4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,455,000
TLXAO : SHARE APPRECIATION RIGHTS	15,764,386
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	304,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	330,437
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13